Entera Bio appoints Miranda Toledano CEO, Dana Yaacov-Garbeli CFO; former CEO Jamas departs with $411K

Entera Bio Ltd.

Appointed Miranda Toledano as CEO effective July 15, 2022; she had served as CBO/CFO and director since 2018.
Toledano's amended employment: annual employer cost $380K, bonus eligibility 60% of base salary, option grant of 600K shares at $1.40.
Additional performance milestone options for 200K shares under long-term incentive.
Dana Yaacov-Garbeli promoted to CFO effective July 15; she was Israel-based CFO since June 2019.
Former CEO Spiros Jamas receives lump sum $411,666.67 (13 months salary) and extension of vested option exercise period for 492,832 shares for two years.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Miranda J. Toledano

Chief Executive Officer

ENTXW · Entera Bio Ltd.

Effective: 2022-07-15
Filed: July 18, 2022, 7:59 PM ET

appointed Miranda J. Toledano, one of the Company’s existing directors and the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, as the Company’s Chief Executive Officer

Departed

Dr. Spiros Jamas

Chief Executive Officer

ENTXW · Entera Bio Ltd.

Effective: 2022-07-15
Successor: Miranda J. Toledano
Filed: July 18, 2022, 7:59 PM ET

separation from the Company of Dr. Spiros Jamas

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Miranda J. Toledano was appointed as Chief Executive Officer at Entera Bio Ltd..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Miranda J. Toledano, one of the Company’s existing directors and the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, as the Company’s Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Spiros Jamas departed as Chief Executive Officer at Entera Bio Ltd..

Action: separated
Role: Chief Executive Officer

Exact text from the filing

separation from the Company of Dr. Spiros Jamas

View on SEC.gov

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-22-002674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.